These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 22566747)

  • 1. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
    Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
    J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
    Samyshkin Y; Guillermin AL; Best JH; Brunell SC; Lloyd A
    J Med Econ; 2012; 15 Suppl 2():6-13. PubMed ID: 22793669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.
    Brändle M; Erny-Albrecht KM; Goodall G; Spinas GA; Streit P; Valentine WJ
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):501-15. PubMed ID: 19640359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Bargiota A; Kourlaba G; Gourzoulidis G; Maniadakis N
    Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.
    Stonehouse A; Walsh B; Cuddihy R
    Diabetes Technol Ther; 2011 Oct; 13(10):1063-9. PubMed ID: 21732798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
    Scott DA; Boye KS; Timlin L; Clark JF; Best JH
    Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    Ryan GJ; Moniri NH; Smiley DD
    Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.
    Gorgojo-Martínez JJ; Gargallo-Fernández MA; Brito-Sanfiel M; Lisbona-Catalán A
    Int J Clin Pract; 2018 Mar; 72(3):e13055. PubMed ID: 29341370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom.
    Woehl A; Evans M; Tetlow AP; McEwan P
    Cardiovasc Diabetol; 2008 Aug; 7():24. PubMed ID: 18694484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
    Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
    Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C; Bergenstal R; Malloy J; Yan P; Walsh B; Malone J; Taylor K
    Diabet Med; 2011 Jun; 28(6):705-14. PubMed ID: 21434995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
    Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
    Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.